同时采用顺铂和放疗治疗的宫颈癌患者生存率与血红蛋白水平的关系:妇科肿瘤组研究  

Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatinand radiotherapy: A Gynecologic Oncology Group Study

作　　者：Winter III W.E. Maxwel G.L. 安妮 

机构地区：[1]Division of Gynecologic Oncology, Walter Reed Army Medical Center, Washington, DC, United States

出　　处：《世界核心医学期刊文摘（妇产科学分册）》2005年第1期57-57,共1页Core Journal in Obstetrics/Gynecology

摘　　要：Objectives. To determine if there is an association of hemoglobin level before or during concurrent cisplatin and radiotherapy (RT) with disease outcome in wo men with locally advanced cervical cancer, and to assess if the association is p articularly significant at a specific interval or time during treatment. Methods . A retrospective review of 494 patients treated on two consecutive prospective Gynecologic Oncology Group (GOG) trials was conducted. Demographic data, patholo gic information, treatment-related factors, and hemoglobin values at baseline a nd during each week of therapy were collected. Cox proportional hazards model wa s performed to evaluate the impact of hemoglobin level on progression-free surv ival (PFS). Results. Of the combined patients, 278 (56%) and 216 (44%) were di agnosed with Stage II and Stage III/IV disease, respectively. Controlling for ag e, race, performance status, disease stage, tumor size, cell type, and duration of radiotherapy, mean hemoglobin values during treatment were predictive of dise ase progression (P < 0.0001). The pretreatment level was not significant when he moglobin levels during treatment were included in the multivariate analysis. Whe n the 6-week treatment coursewas divided into 2-week periods (early,middle, an d late), analysis revealed hemoglobin values during the late period were the mos t predictive of disease progression (P = 0.0289). Conclusions. Hemoglobin levels during combined radiotherapy and cisplatin were independent predictors of treat ment outcome in advanced cervical carcinoma. The pretreatment level was not a si gnificant predictor of outcome when hemoglobin levels during treatment were incl uded in the multivariate regression model. Levels in the last part of treatment were the most predictive of disease recurrence and survival.Objectives. To determine if there is an association of hemoglobin level before or during concurrent cisplatin and radiotherapy (RT) with disease outcome in wo men with locally advanced cervical cancer, and to assess if the association is p articularly significant at a specific interval or time during treatment. Methods . A retrospective review of 494 patients treated on two consecutive prospective Gynecologic Oncology Group (GOG) trials was conducted. Demographic data, patholo gic information, treatment-related factors, and hemoglobin values at baseline a nd during each week of therapy were collected. Cox proportional hazards model wa s performed to evaluate the impact of hemoglobin level on progression-free surv ival (PFS). Results. Of the combined patients, 278 (56%) and 216 (44%) were di agnosed with Stage II and Stage III/IV disease, respectively. Controlling for ag e, race, performance status, disease stage, tumor size, cell type, and duration of radiotherapy, mean hemoglobin values during treatment were predictive of dise ase progression (P < 0.0001). The pretreatment level was not significant when he moglobin levels during treatment were included in the multivariate analysis. Whe n the 6-week treatment coursewas divided into 2-week periods (early,middle, an d late), analysis revealed hemoglobin values during the late period were the mos t predictive of disease progression (P = 0.0289). Conclusions. Hemoglobin levels during combined radiotherapy and cisplatin were independent predictors of treat ment outcome in advanced cervical carcinoma. The pretreatment level was not a si gnificant predictor of outcome when hemoglobin levels during treatment were incl uded in the multivariate regression model. Levels in the last part of treatment were the most predictive of disease recurrence and survival.

关 键 词：妇科肿瘤 血红蛋白水平 晚期宫颈癌 放射疗法 统计学数据 模型评估 存活者 细胞类型 多变量分析 回归模型分析 

分 类 号：R737.33[医药卫生—肿瘤]